Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 18.60
Change Today +0.10 / 0.54%
Volume 1.6M
BOLT On Other Exchanges
Symbol
Exchange
Tel Aviv
OTC US
As of 10:24 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

bio light israeli life scien (BOLT) Snapshot

Open
$18.50
Previous Close
$18.50
Day High
$18.90
Day Low
$18.00
52 Week High
04/1/14 - $21.80
52 Week Low
09/28/14 - $13.10
Market Cap
97.0M
Average Volume 10 Days
1.6M
EPS TTM
$-0.06
Shares Outstanding
521.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIO LIGHT ISRAELI LIFE SCIEN (BOLT)

Related News

No related news articles were found.

bio light israeli life scien (BOLT) Related Businessweek News

No Related Businessweek News Found

bio light israeli life scien (BOLT) Details

BioLight Israeli Life Sciences Investments Ltd. engages in the research and development, and in investments in companies in the biomed sector. The company operates through two segments, Glaucoma and Dry Eye Syndrome, and Cancer Diagnostics. The Glaucoma and Dry Eye Syndrome segment develops and markets a nonpenetrating CO2 laser assisted filtration surgery technology for treating glaucoma; develops a kit that analyzes tear fluid for screening and monitoring dry eye syndrome and its treatment by examining the amount and quality of tear fluid; and researches and develops a sub-conjunctival drug insert technology for the controlled release of ophthalmic medications. The Cancer Diagnostics segment developing medical solutions for cancer diagnostics. It develops CellDetect, a diagnostic technology for the detection of cancer cells through discriminate staining of cancer and pre-cancer cells among normal cells for various cancer indications; owns the development rights to an innovative diagnostic kit for identifying carriers of deleterious BRCA mutations, who are at increased risk to develop breast and ovarian cancer; develops a diagnostic kit for the early identification of colorectal cancer (CRC) using a q-PCR based blood test and a differentiating diagnostic test based on a panel of biomarkers, targeted towards CRC patients found eligible for biological therapy that inhibits the EGFR receptor. This segment also develops and commercializes diagnostic kit for detecting a genetic profile that enhances the risk of developing a severe side effect from the use of Bisphosphonate Related Osteonecrosis of the Jaw; and participates in the funding of the NCBI's Nofar study of predictive biochemical-markers for the development of brain metastases from lung cancer. The company was founded in 2005 and is based in Tel Aviv, Israel.

24 Employees
Last Reported Date: 03/27/14
Founded in 2005

bio light israeli life scien (BOLT) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 798.0K
Chief Financial Officer
Total Annual Compensation: 409.0K
Compensation as of Fiscal Year 2013.

bio light israeli life scien (BOLT) Key Developments

BioLight Reports Positive Clinical Study Findings for its TeaRx Diagnostic Parameters for Dry Eye Syndrome

BioLight Life Sciences Investments Ltd. announced the completion of a U.S. clinical study, conducted by Ora Inc.Andover, MA, designed to compare widely used benchmark tests for dry eye with its TeaRx diagnostic parameters that test components of tear film. Positive statistical correlations were identified between TeaRx diagnostic parameters and widely used benchmark tests for dry eye syndrome The TeaRx diagnostic tests are developed by DiagnosTear Ltd., one of BioLight's subsidiaries. In this prospective study consisting of approximately 200 subjects, widely-used benchmark tests for dry eye were compared with the TeaRx™ diagnostic parameters, including Schirmer's test, TFBUT (Tear-Film Break-Up Time), staining of corneal and conjunctival epithelial cell damage and patient questionnaires. The study analysis was based on testing the sample extremes, quartiles 1 and 4, representing those enrolled subjects with larger differences for each metric. This approach resulted in positive statistical correlations that showed many of the predicted trends and correlations between the widely used benchmark tests and the TeaRx™ diagnostic parameters tests which measure tear film components. The positive correlation that was identified between certain TeaRx™ diagnostic parameters and subjective testing standards that are widely used indicates a unique ability for improving the dry eye syndrome diagnosis by objective quantification of measures over subjective evaluation.

BioLight Life Sciences Investments Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence with the Celldetect® Non-Invasive Test

BioLight Life Sciences Investments Ltd. announced that a blinded, multi-center clinical study of the CellDetect® non-invasive test for detecting bladder cancer in urine, successfully achieved the study's primary endpoint for effectively detecting the recurrence of bladder cancer in subjects with a history of the disease. The CellDetect® urine test successfully identified cancerous cells in urine samples in patients with a history of the disease, with reported sensitivity of 84.4% and specificity of 82.7% for the study's primary endpoint. The CellDetect® technology is being developed by Micromedic Technologies, BioLight's cancer diagnostics subsidiary, and allows an accurate diagnosis of cancerous and precancerous cells, based on a unique combination of color and morphology by utilizing a proprietary kit containing unique extract and dyes. As a result of these successful study results, Micromedic plans to secure CE mark approval for a European launch of the non-invasive test later this year, as well as to submit a Pre-IDE to the U.S. Food and Drug Administration (FDA). The blinded clinical study was conducted in nine medical centers in Israel, where urine samples from 217 subjects with a history of bladder cancer were tested. The study population included 121 healthy subjects and 96 patients currently suffering from the disease. The results of the CellDetect® urine test were compared with results from biopsy or cystoscopy, in cases where biopsies were not taken. The results also indicated that the CellDetect® urine test's negative predictive value (NPV), defined as the probability that a patient having a negative result doesn't suffer from the disease, was 98.5%. In addition to its high sensitivity for advanced stage tumors and high-grade malignancy, the test was also found to exhibit high sensitivity for early stage tumors and low-grade malignancies, which are difficult to identify using other non-invasive tests currently available on the market. These findings indicate that the method is adequately sensitive for the purpose of accurate and early detection of the recurrence of the disease. The secondary endpoint showed that the sensitivity of other non-invasive comparator tests, urine cytology, BTA stat and NMP22 BladderCheck, was 50.0%, 68.8% and 17.4%, respectively. These findings further underscore the potential of the CellDetect® test as an accurate, reliable and a non-invasive tool for monitoring the recurrence of bladder cancer. Micromedic also plans to utilize reimbursement existing codes for monitoring bladder cancer recurrence and will continue to advance the CellDetect® technology for the diagnosis of additional cancer indications.

BioLight Life Sciences Investments Ltd. Announces IOPtiMate™ Distribution Agreement in Hong Kong and Macao

BioLight Life Sciences Investments Ltd. announced the signing of an exclusive distribution agreement for the sale and marketing of the IOPtiMate™ system in Hong Kong and Macao, including the purchase of at least 9 systems during the initial term of the agreement. The IOPtiMate™ system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives. This distribution agreement in Hong Kong and Macao, along with the distributer commitment to purchase at least 9 IOPtiMate[TM] systems, is the result of an intensive marketing campaign by BioLight in Asia for the IOPtiMate™ system as part of the Company's focus on markets with unmet needs for better solutions to treat glaucoma.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOLT:IT 18.60 +0.10

BOLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BOLT.
View Industry Companies
 

Industry Analysis

BOLT

Industry Average

Valuation BOLT Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO LIGHT ISRAELI LIFE SCIEN, please visit www.bio-light.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.